Pharmicell Co., Ltd.

KSC:005690.KS

$5400 KRW

-$70 (-1.28%)

Volume
164.38K
Average Volume
395.36K
Market Capitalization
$324.02B
P/E Ratio
75.87
Dividend Yield
0.00%
Price Target
$
Year High
$10540.00
Year Low
$5290.00
Payout Ratio
$0.00
Current Ratio
$0.00

Industry, Sector & symbol

Stock Exchange KSE
CEO Hyun-Soo Kim
Industry Biotechnology
Sector Healthcare
Current Symbol 005690.KS
CUSIP None
CIK None
Web https://www.pharmicell.com
Phone 82 2 3496 0114
Currency KRW
Employees None
Country KR

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 0.00
Quick Ratio 0.00
Cash Ratio 0.00

Sales & Book Value

Annual Sales $56.23B
Price / Sales 5.76
Cash Flow 117.58
Price / Cash Flow 47.03
Price / Book 3.92

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $0
Trailing P/E Ratio 75.87
PEG Ratio 3.62
P/E Growth 3.62
Net Income $3.79B
Net Margin 7.42%
Pretax Margin 8.15%
Return on Equity 5.15%
Return on Assets 4.49%

Financials Score

AltmanZ Score
Piotroski Score 7.00
Working Capital -
Total Assets 92.89B
Ebit 1.21B
Market Cap 324.02B
Total Liabilities -

Poll Results

About Pharmicell Co., Ltd. (KSC:005690.KS) Stock

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, ... eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Frequently Asked Questions

What is the current Pharmicell Co., Ltd. (005690.KS) stock price?

Pharmicell Co., Ltd.(KSC:005690.KS) stock price is $5400 in the last trading session. During the trading session, 005690.KS stock reached the peak price of $10540.0 while $5290.0 was the lowest point it dropped to. The percentage change in 005690.KS stock occurred in the recent session was --1.28% while the dollar amount for the price change in 005690.KS stock was -$-70.

005690.KS's industry and sector of operation?

The KSC listed 005690.KS is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 005690.KS?

Hyun-Soo Kim | Chief Executive Officer and Inside Director
|
|
|
|

How many employees does 005690.KS have?

Number of 005690.KS employees currently stands at None. 005690.KS operates from Ssangbong Building, Seoul, None None, KR.

Link for 005690.KS official website?

Official Website of 005690.KS is: https://www.pharmicell.com

How do I contact 005690.KS?

005690.KS could be contacted at phone #82 2 3496 0114 and can also be accessed through its website. 005690.KS operates from Ssangbong Building, Seoul, None None, KR.

How many shares of 005690.KS are traded daily?

The average number of 005690.KS shares traded daily for last 3 months was 395.36K.

What is the market cap of 005690.KS currently?

The market value of 005690.KS currently stands at $324.02B with its latest stock price at $5400